Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neurocrine Biosciences, Inc.

https://www.neurocrine.com/

Latest From Neurocrine Biosciences, Inc.

Afrigen MD: WTO IP Waiver Important From ‘Freedom To Operate’ Standpoint

Afrigen’s MD, Petro Terblanche, discusses the operational freedom that the WTO intellectual property waiver provides for its COVID-19 vaccine being developed under the wider WHO-backed mRNA technology transfer hub initiative. The executive doesn’t anticipate big pharma pushback but says the alliance will “test the system”, though others believe the waiver in its current form doesn’t count for much.

Commercial Coronavirus COVID-19

Time To Shop? SK Sees ‘Biggest Opportunity’ For Biotech Investment

At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.

South Korea Deals

The Biopharma A List: Taking The Pulse Of Newco Creation

The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.

StartUps and SMEs Financing

Jardiance, Trajenta Wins: Boehringer Takes Rough With Smooth In India

Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?

India Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register